Latest Insider Transactions at Encompass Health Corp (EHC)
This section provides a real-time view of insider transactions for Encompass Health Corp (EHC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Encompass Health Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Encompass Health Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 25
2025
|
Douglas E Coltharp EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,079
-1.74%
|
$107,900
$100.63 P/Share
|
|
Feb 25
2025
|
John Patrick Darby EVP, Gen Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
509
-0.63%
|
$50,900
$100.63 P/Share
|
|
Feb 25
2025
|
Elissa Joy Charbonneau Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
506
-2.96%
|
$50,600
$100.63 P/Share
|
|
Feb 25
2025
|
Edmund Fay Sr. Vice Pres. and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
384
-0.38%
|
$38,400
$100.63 P/Share
|
|
Feb 25
2025
|
Mark J Tarr President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,896
-0.54%
|
$289,600
$100.63 P/Share
|
|
Feb 25
2025
|
Andrew L Price Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
410
-0.58%
|
$41,000
$100.63 P/Share
|
|
Feb 24
2025
|
Douglas E Coltharp EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
927
-1.47%
|
$89,919
$97.53 P/Share
|
|
Feb 24
2025
|
John Patrick Darby EVP, Gen Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-0.54%
|
$42,389
$97.53 P/Share
|
|
Feb 24
2025
|
Elissa Joy Charbonneau Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
435
-2.48%
|
$42,195
$97.53 P/Share
|
|
Feb 24
2025
|
Edmund Fay Sr. Vice Pres. and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
374
-0.37%
|
$36,278
$97.53 P/Share
|
|
Feb 24
2025
|
Mark J Tarr President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,488
-0.47%
|
$241,336
$97.53 P/Share
|
|
Feb 24
2025
|
Andrew L Price Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
401
-0.57%
|
$38,897
$97.53 P/Share
|
|
Feb 20
2025
|
Douglas E Coltharp EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,557
+6.73%
|
-
|
|
Feb 20
2025
|
Elissa Joy Charbonneau Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,939
+9.95%
|
-
|
|
Feb 20
2025
|
John Patrick Darby EVP, Gen Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
2,216
+2.66%
|
-
|
|
Feb 20
2025
|
Edmund Fay Sr. Vice Pres. and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
1,404
+1.37%
|
-
|
|
Feb 20
2025
|
Mark J Tarr President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
12,152
+2.22%
|
-
|
|
Feb 20
2025
|
Andrew L Price Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,538
+2.13%
|
-
|
|
Feb 13
2025
|
Andrew L Price Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,042
-6.79%
|
$494,116
$98.29 P/Share
|
|
Jan 16
2025
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
375
+2.88%
|
$35,250
$94.38 P/Share
|
|
Jan 16
2025
|
Edward M Christie Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
292
+5.84%
|
$27,448
$94.4 P/Share
|
|
Jan 15
2025
|
Nancy M Schlichting Director |
BUY
Grant, award, or other acquisition
|
Direct |
36
+0.18%
|
-
|
|
Jan 15
2025
|
Terrance Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
25
+0.18%
|
-
|
|
Jan 15
2025
|
Patricia Anne Maryland Director |
BUY
Grant, award, or other acquisition
|
Direct |
25
+0.19%
|
-
|
|
Jan 15
2025
|
Kevin J. O'Connor Director |
BUY
Grant, award, or other acquisition
|
Direct |
14
+0.17%
|
-
|
|
Jan 15
2025
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
16
+0.13%
|
-
|
|
Jan 15
2025
|
Greg D Carmichael Director |
BUY
Grant, award, or other acquisition
|
Direct |
25
+0.15%
|
-
|
|
Jan 15
2025
|
Joan E Herman Director |
BUY
Grant, award, or other acquisition
|
Direct |
83
+0.18%
|
-
|
|
Jan 15
2025
|
Leslye G Katz Director |
BUY
Grant, award, or other acquisition
|
Direct |
83
+0.18%
|
-
|
|
Jan 15
2025
|
Edward M Christie Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.14%
|
-
|
|
Jan 01
2025
|
Douglas E Coltharp EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,438
-17.52%
|
$1,144,296
$92.35 P/Share
|
|
Jan 01
2025
|
Elissa Joy Charbonneau Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,991
-16.09%
|
$275,172
$92.35 P/Share
|
|
Jan 01
2025
|
Edmund Fay Sr. Vice Pres. and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,291
-2.24%
|
$210,772
$92.35 P/Share
|
|
Jan 01
2025
|
Mark J Tarr President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,609
-5.7%
|
$2,908,028
$92.35 P/Share
|
|
Jan 01
2025
|
John Patrick Darby EVP, Gen Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
5,917
-6.98%
|
$544,364
$92.35 P/Share
|
|
Jan 01
2025
|
Andrew L Price Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,446
-3.19%
|
$225,032
$92.35 P/Share
|
|
Nov 13
2024
|
Douglas E Coltharp EVP & Chief Financial Officer |
BUY
Bona fide gift
|
Indirect |
65,229
+50.0%
|
-
|
|
Nov 13
2024
|
Douglas E Coltharp EVP & Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
65,229
-47.88%
|
-
|
|
Oct 17
2024
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
362
+2.87%
|
$35,114
$97.53 P/Share
|
|
Oct 17
2024
|
Edward M Christie Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
283
+6.03%
|
$27,451
$97.63 P/Share
|
|
Oct 15
2024
|
Terrance Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
24
+0.18%
|
-
|
|
Oct 15
2024
|
Kevin J. O'Connor Director |
BUY
Grant, award, or other acquisition
|
Direct |
14
+0.17%
|
-
|
|
Oct 15
2024
|
Nancy M Schlichting Director |
BUY
Grant, award, or other acquisition
|
Direct |
35
+0.18%
|
-
|
|
Oct 15
2024
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
16
+0.13%
|
-
|
|
Oct 15
2024
|
Leslye G Katz Director |
BUY
Grant, award, or other acquisition
|
Direct |
81
+0.18%
|
-
|
|
Oct 15
2024
|
Patricia Anne Maryland Director |
BUY
Grant, award, or other acquisition
|
Direct |
24
+0.18%
|
-
|
|
Oct 15
2024
|
Edward M Christie Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.15%
|
-
|
|
Oct 15
2024
|
Joan E Herman Director |
BUY
Grant, award, or other acquisition
|
Direct |
81
+0.18%
|
-
|
|
Oct 15
2024
|
Greg D Carmichael Director |
BUY
Grant, award, or other acquisition
|
Direct |
24
+0.14%
|
-
|
|
Aug 13
2024
|
Douglas E Coltharp EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,260
-4.13%
|
$1,054,360
$86.68 P/Share
|